Nxera Pharma is a brand-new company record, and its full research profile isn't ready yet.
nxera.lifeCrawled Oct 25, 2026
Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients Journal of Neurosurgery
The NxWave platform supports a patient-driven approach to unlock GPCR potential for structure-based drug design and life-changing medicine development.
Nxera Pharma develops medicines in-house and through partnerships to maximize patient access.
Representative Executive Officer, President and Chief Executive Officer Chris Cargill joined Nxera Pharma in September 2017 as Head of Investor Relations and Communications and was appointed as Executive Vice President and Chief Financial Officer in November 2018.
Hironoshin was appointed as Executive Vice President, Chief Financial Officer in March 2022.
Representative Christopher Cargill Established June 22, 1990 Capital Stock 46,070 million yen
The company aims to build a technology-driven pharmaceutical business to improve patient outcomes globally.
Nxera's corporate headquarters and clinical operations are in Tokyo and Seoul. Its R&D facilities are in Cambridge, UK, and its corporate offices are in London and Basel.
Bringing new medicines to patients in Japan and South Korea (and other APAC countries) offers tremendous potential for growth as part of a global commercialization strategy. However, the challenges are significant, and range from high costs to the complexities of regional regulations and cultural sensitivities.
Nxera Pharma accelerates life-changing medicine development by investing in science and technology, using its NxWave platform for GPCR-based drug design.